Lyell Immunopharma, Inc. $LYEL Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 2.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,604,676 shares of the company's stock after selling 41,111 shares during the period. Charles Schwab Investment Management Inc. owned 0.54% of Lyell Immunopharma worth $863,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LYEL. Foresite Capital Management V LLC purchased a new position in shares of Lyell Immunopharma in the 4th quarter valued at approximately $5,205,000. venBio Partners LLC purchased a new position in shares of Lyell Immunopharma in the 4th quarter valued at approximately $4,545,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Lyell Immunopharma in the 4th quarter valued at approximately $887,000. D. E. Shaw & Co. Inc. raised its position in shares of Lyell Immunopharma by 104.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 966,265 shares of the company's stock valued at $618,000 after purchasing an additional 493,639 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Lyell Immunopharma in the 4th quarter valued at approximately $162,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Stock Up 3.7%

Shares of NASDAQ:LYEL traded up $0.43 during trading on Friday, hitting $12.15. 18,409 shares of the stock traded hands, compared to its average volume of 26,417. The company has a market cap of $233.40 million, a price-to-earnings ratio of -0.50 and a beta of -0.19. The company has a fifty day moving average price of $10.67 and a two-hundred day moving average price of $10.35. Lyell Immunopharma, Inc. has a 52-week low of $7.65 and a 52-week high of $32.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.80) by $0.91. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative return on equity of 85.58%. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. On average, equities research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LYEL shares. Wall Street Zen raised shares of Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Monday, September 1st. HC Wainwright reissued a "neutral" rating and set a $10.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, June 24th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Lyell Immunopharma has a consensus rating of "Reduce" and a consensus price target of $15.00.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.